Arcus Biosciences, Inc.

Jeremy Fournier

Manmohan Reddy Leleti

Kenneth Victor Lawson

Joel Worley Beatty

Samuel Lawrie Drew

Jay Patrick Powers

Brandon Reid Rosen

Guillaume Mata

Balint Gal

Artur Karenovich Mailyan

Kai Yu

Matthew Epplin

Clayton Hardman

Jaroslaw Kalisiak

Xuelei Yan

Debashis Mandal

Erick Allen Lindsey

Rhiannon Thomas-Tran

Jenna Leigh Jeffrey

Laurent Pierre Paul Debien

Anh Thu Tran

Zhang Wang

Steven Donald Jacob

Karl T Haelsig

Rebecca Louise Grange

Masa Podunavac

Dongdong Liu

The present disclosure describes processes and intermediates useful for preparing a compound of Formula (Xa) or Formula (Xb). The processes and intermediates can be used to prepare the compounds of the disclosure at multigram or kilogram scale.

Process for preparing tetralin compounds

The present disclosure is directed to compounds that are inhibitors of HIF-2α having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Inhibitors of HIF-2α and methods of use thereof

Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

CD73 inhibitors

Growing community of inventors

Fremont, CA, United States of America

Jeremy Fournier